GNS561, A NEW ORAL CLINICAL-STAGE SMALL MOLECULE COMBINED WITH ANTI-PD1 SHOWED REMARKABLE ANTI-TUMOR EFFECTS IN A TRANSGENIC IMMUNOCOMPETENT HEPATOCELLULAR CARCINOMA MOUSE MODEL (ASV-B)

Meeting Abstract: 1993

Rachid, Madani , Tijeras-Raballand, Annemilai , Cindy Serdjebi (1) , Sonia Brun (2) , Christelle Ansaldi , Eric Raymond , Philippe Halfon (3, 4)

1 CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie
2 IRIM - Institut de Recherche en Infectiologie de Montpellier
3 MEPHI - Microbes évolution phylogénie et infections
4 Hôpital Européen [Fondation Ambroise Paré - Marseille]

Domaines: Bactériologie; Virologie; Parasitologie; Cardiologie et système cardiovasculaire; Maladies émergentes; Maladies infectieuses

Rachid, Madani, Tijeras-Raballand, Annemilai, Cindy Serdjebi, Sonia Brun, Christelle Ansaldi, et al.. GNS561, A NEW ORAL CLINICAL-STAGE SMALL MOLECULE COMBINED WITH ANTI-PD1 SHOWED REMARKABLE ANTI-TUMOR EFFECTS IN A TRANSGENIC IMMUNOCOMPETENT HEPATOCELLULAR CARCINOMA MOUSE MODEL (ASV-B). Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Nov 2019, Boston, MA, United States. pp.1189A. ⟨hal-02466433⟩